White label ELPA - ClinicalTrials.eu

Study on Vedolizumab for Children with Moderate to Severe Ulcerative Colitis

Not recruiting

3 1 1 1
Long-Term Safety Study of Valoctocogene Roxaparvovec for Patients with Severe Hemophilia A

Not recruiting

3 1 1 1
Investigated diseases:
- Factor VIII deficiency
Study of ALX148 and Azacitidine for Untreated Higher Risk Myelodysplastic Syndrome Patients

Not recruiting

1 1 1 1
Investigated diseases:
- Myelodysplastic syndrome
Study Comparing Savolitinib and Durvalumab with Sunitinib and Durvalumab for Patients with Advanced Papillary Renal Cell Carcinoma

Not recruiting

3 1 1 1
Investigated diseases:
- Clear cell papillary renal cell carcinoma
+2
Study on Long-term Safety of Seralutinib for Patients with Pulmonary Arterial Hypertension

Not recruiting

3 1 1
Investigated diseases:
- Pulmonary arterial hypertension
+10
Study of Lenvatinib for Children and Young Adults with Relapsed or Refractory Solid Tumors, Including High Grade Glioma and Rhabdomyosarcoma

Not recruiting

2 1 1
Investigated diseases:
Study Comparing Lorlatinib and Crizotinib for Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer

Not recruiting

3 1 1 1
Investigated diseases:
+2
Study on the Long-Term Safety of Tavapadon for Patients with Parkinson’s Disease

Not recruiting

3 1 1
Investigated diseases:
- Parkinson’s disease
+2
Study of Nivolumab and Relatlimab for Patients with Resectable Non-Small Cell Lung Cancer

Not recruiting

2 1 1 1
Investigated diseases:
- Non-small cell lung cancer
Study of Entrectinib in Children and Adolescents with Advanced or Metastatic Solid Tumors or Primary CNS Tumors with No Satisfactory Treatment Options

Not recruiting

1 1 1
Investigated diseases:
- Malignant mast cell neoplasm

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies